MGNX Share Price Performance
US$1.61
-1.62 (-50.15%)
19.5% undervalued intrinsic discount
US$2.00
Fair Value
Price US$1.61
AnalystLowTarget US$2.00
AnalystConsensusTarget US$3.75
AnalystHighTarget US$5.00
Fair ValueUS$2.00
Share Pricen/a
MacroGenics, Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
MGNX Community Narratives
AN
Fair Value US$2 19.5% undervalued intrinsic discount
Immuno-oncology Setbacks And Cash Burn Will Block Progress Despite Promise
0users have liked this narrative
1users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$3.75 57.1% undervalued intrinsic discount
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
Fair Value US$5 67.8% undervalued intrinsic discount
Advancing DART Platform Will Drive Targeted Immuno-Oncology Gains Despite Setbacks
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Key Takeaways Future revenue growth potential hinges on successful trial outcomes and product approvals in ongoing and upcoming clinical studies. A robust pipeline and financial sustainability support continued R&D efforts, reinforcing prospects for growth if new treatments prove effective.Read more
45
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
US$3.75
57.1% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
-20.05% p.a.
Profit Margin
14.17%
Future PE
25.52x
Price in 2028
US$4.74
Advancing DART Platform Will Drive Targeted Immuno-Oncology Gains Despite Setbacks
Key Takeaways Lorigerlimab and LINNET trials could unlock new market opportunities, pricing power, and sustained earnings growth in largely untapped cancer segments. Strong cash reserves, pipeline expansion, and attractive platform technologies make MacroGenics a likely acquisition target with multi-year growth potential.Read more
19
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$5
67.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
-16.6% p.a.
Profit Margin
14.17%
Future PE
29.87x
Price in 2028
US$6.29
Immuno-oncology Setbacks And Cash Burn Will Block Progress Despite Promise
Key Takeaways Heavy reliance on milestone payments, regulatory approvals, and clinical trial success creates persistent uncertainty for revenue and margin growth. High R&D spending and limited commercialized products increase financial strain, raising risks of shareholder dilution and constrained profitability.Read more
11
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
0users have followed this narrative
AN
US$2
19.5% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
-37.36% p.a.
Profit Margin
18.33%
Future PE
21.71x
Price in 2028
US$2.51
Trending Discussion
Recently Updated Narratives
AN
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Fair Value: US$3.75 57.1% undervalued intrinsic discount
8 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Immuno-oncology Setbacks And Cash Burn Will Block Progress Despite Promise
Fair Value: US$2 19.5% undervalued intrinsic discount
0 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Advancing DART Platform Will Drive Targeted Immuno-Oncology Gains Despite Setbacks
Fair Value: US$5 67.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
MacroGenics, Inc. Key Details
About MGNX
- Founded
- 2000
- Employees
- 341
- CEO
- WebsiteView website
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
